Neurolign Technologies Inc.

What Neurolign Technologies Inc. does

Neurolign Technologies Inc., doing business as Spryson America, is a clinical-stage medical device and AI diagnostics company founded in 2018 and headquartered in Toronto, Canada with operational presence in Pittsburgh, Pennsylvania. The company employs 1-10 people and operates as a privately held entity.

The company's core platform, NeuroAI, combines artificial intelligence algorithms with eye-tracking, videonystagmography (VNG), and rotary-chair hardware to perform neurological diagnostics. Its commercial product suite centers on the DX200 VNG/Eye Tracking Platform as the hardware foundation, with vertically integrated software modules spanning PD-Check (a Parkinson's disease screening tool for which the company has applied for FDA Breakthrough Device designation), a TBI/Concussion diagnosis module in clinical evaluation, and broader clinic workflow solutions. The company claims to have launched what it describes as the "world's largest Parkinson's research initiative" and has produced peer-reviewed research on OVRT-C responses in pediatric populations, published in Experimental Brain Research.

Neurolign derives revenue through one-time enterprise licensing of its combined hardware/software platform, selling into specialized clinical accounts. Identified target segments include adult neurology clinics, sports medicine and concussion practices, pediatric neurology centers, and the personal injury/medico-legal channel. The business remains at an early commercial stage, with no disclosed funding rounds or named enterprise customers.

Name

Neurolign Technologies Inc.

Legal name

Spryson America, Inc.

Website

https://neurolign.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurolign Technologies (operating as Spryson America) develops AI-powered neurological diagnostic platforms combining eye-tracking and proprietary biomarkers, serving neurology, sports medicine, and pediatric neurology clinics through enterprise licensing of its NeuroAI platform.

Ownership category

akta.pro rank

Product category

Neurological Diagnostic Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Pediatric Neurology (HLAKAIAK)

Keywords

• Neurological diagnostics
• Video nystagmography equipment
• AI medical imaging
• Eye-tracking diagnostics
• Concussion assessment technology

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. NeuroAI Diagnostic Platform: AI-driven neurological diagnostic platform sold to healthcare institutions, clinics, and hospitals for clinical decision support and diagnostic assessments

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Neurolign Technologies Inc. (operating as Spryson America) develops and sells AI-driven neurological diagnostic platforms combining Video Nystagmography (VNG) and Rotary Chair hardware with proprietary eye-tracking and biomarker analytics. Its flagship NeuroAI system enables early detection, progression monitoring, and treatment optimization for Parkinson's disease, traumatic brain injury/concussion, and pediatric neurological conditions, sold to healthcare institutions, specialty clinics, and research facilities.

Product overview

Neurolign Technologies Inc. (operating as Spryson America) offers NeuroAI, a unified AI-driven neurological diagnostic platform that integrates VNG and rotary chair technology. The portfolio consists of the DX200 VNG/Eye Tracking Platform as the core hardware/software foundation, with NeuroAI as the AI analytics layer providing predictive diagnostics. Add-on modules include PD-Check for Parkinson's disease detection (currently seeking FDA Breakthrough Device Status), TBI/Concussion Diagnosis for traumatic brain injury assessment, and Clinic Solutions for practice integration. The platform leverages advanced eye-tracking, proprietary neurological biomarkers, and biometric data integration to enable early detection, progression monitoring, and treatment optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• NeuroAI Diagnostic Platform AI-driven neurological diagnostic platform that integrates Video Nystagmography (VNG) and Rotary Chair technology with proprietary biomarkers and advanced eye-tracking for precise, personalized diagnostic outcomes. Sold to healthcare institutions, neurology clinics, and research facilities for early detection, progression monitoring, and treatment optimization of Parkinson's disease, TBI/concussion, and pediatric neurological conditions.
• DX200 VNG/Eye Tracking Platform Industry-leading video nystagmography (VNG) and eye tracking hardware/software platform serving as the foundational device for NeuroAI diagnostics, capturing eye movement data for neurological assessment in clinical settings.
• PD-Check Revolutionary Parkinson's disease detection protocol that applies advanced eye-tracking with proprietary neurological biomarkers for non-invasive early detection, progression monitoring, and treatment optimization. Sold to neurology and movement disorder clinics; FDA Breakthrough Device designation application in progress.
• TBI/Concussion Diagnosis Module AI-powered traumatic brain injury and concussion diagnosis tool using NeuroAI's advanced eye-tracking and biometrics technology for real-time, objective data collection and assessment. Currently under clinical evaluation. Targeted at sports medicine and concussion clinics for return-to-play and recovery monitoring decisions.
• Clinic Solutions Clinical workflow solutions designed to enable clinics to integrate NeuroAI technology into their practice for enhanced diagnostic capabilities and streamlined operations.

Quantifiable outcome

• Real-time processing delivers results in minutes, not days

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• RightEye: RightEye builds eye-tracking based clinical assessments for concussion, brain health, and vision performance, sold into optometry, sports medicine, and primary care. Both companies commercialize AI-augmented eye-tracking diagnostics to clinical practices, with overlapping concussion and neurological-assessment value propositions.
• Oculogica: Oculogica offers an FDA-cleared eye-tracking based concussion and brain-injury diagnostic test, competing head-on with Spryson/N Neurolign's TBI-Check in sports medicine, pediatric, and emergency department settings. Both companies pursue objective ocular-movement biomarkers for TBI assessment.
• SyncThink: SyncThink develops eye-tracking based concussion and brain-performance assessment technology (notably EYE-SYNC), serving sports medicine, military, and clinical concussion markets comparable to Spryson's TBI-Check. Both compete for the same objective concussion diagnosis budget at concussion clinics, sports programs, and military providers.
• Neuro Kinetics: Neuro Kinetics manufactures VNG and eye-tracking based neuro-otology diagnostic systems used in concussion, vestibular, and neurological assessment, overlapping directly with Spryson's DX200 and TBI-Check applications. Both sell objective eye-movement diagnostic platforms into clinical neuro-otology channels.
• Interacoustics: Interacoustics is a leading manufacturer of vestibular and balance diagnostic equipment, including VNG systems and rotary chairs - the same core hardware categories Spryson/N Neurolign's DX200 platform competes with. Both companies sell diagnostic instrumentation into audiology, ENT, and neurology clinics, making them the most direct competitive peer.
• Micromedical Technologies: Micromedical Technologies (now part of the broader vestibular diagnostics ecosystem) specializes in VNG, rotary chair, and balance assessment equipment directly comparable to Spryson's DX200 platform. Both target ENT and neurology practices for ocular-motor and vestibular diagnostics.

Broad incumbents

• Compumedics: Compumedics is an established global manufacturer of EEG, sleep, and neurological monitoring equipment used across research and clinical neurology. It serves a broader neurodiagnostic portfolio and represents the type of incumbent that could expand into eye-tracking-based diagnostics if the category scales.
• Natus Medical: Natus Medical is a large, established neurodiagnostic device maker (EEG, EMG, sleep, neuro-monitoring) serving hospitals globally. While not specialized in VNG/rotary chair, Natus competes in adjacent neurological diagnostic equipment categories and has the scale and channel relationships to enter Spryson/N Neurolign's space.

Emerging players

• EyeSeeCam: EyeSeeCam produces video head impulse test (vHIT) and eye-tracking camera systems for vestibular and neurological diagnostics. It addresses a narrower vestibular niche than Spryson but competes for the same clinical eye-tracking diagnostic budget at otolaryngology and neurology clinics.
• Bertec (Balance & Mobility): Bertec manufactures balance, postural-control, and vestibular assessment systems used alongside VNG and rotary-chair diagnostics in concussion and neurology clinics. It is an adjacent, partially overlapping competitor in the broader neurological/vestibular diagnostic equipment category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SprysonNeuroAI
• YouTubeyoutube.com/@SprysonNeuroAI
• Facebookfacebook.com/spryson
• Instagraminstagram.com/sprysonusa

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurolign Technologies Inc.